BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9178899)

  • 21. Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene.
    Akasaka T; Akasaka H; Ueda C; Yonetani N; Maesako Y; Shimizu A; Yamabe H; Fukuhara S; Uchiyama T; Ohno H
    J Clin Oncol; 2000 Feb; 18(3):510-18. PubMed ID: 10653866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aberrant class switching juxtaposes c-myc with a middle repetitive element (LINE) and an IgH intron in two spontaneously arising rat immunocytomas.
    Pear WS; Nelson SF; Axelson H; Wahlström G; Bazin H; Klein G; Sümegi J
    Oncogene; 1988 May; 2(5):499-507. PubMed ID: 3131719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulatory elements in the immunoglobulin heavy chain gene 3'-enhancers induce c-myc deregulation and lymphomagenesis in murine B cells.
    Wang J; Boxer LM
    J Biol Chem; 2005 Apr; 280(13):12766-73. PubMed ID: 15687498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of genetic factors associated with the immunoglobulin heavy chain locus on the development of benign monoclonal gammapathy in ageing IgH-congenic mice.
    van den Akker TW; de Glopper-van der Veer E; Radl J; Benner R
    Immunology; 1988 Sep; 65(1):31-5. PubMed ID: 3141270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
    Cutrona G; Carpaneto EM; Ponzanelli A; Ulivi M; Millo E; Scarfì S; Roncella S; Benatti U; Boffa LC; Ferrarini M
    Cancer Res; 2003 Oct; 63(19):6144-8. PubMed ID: 14559793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tp53 deletion in B lineage cells predisposes mice to lymphomas with oncogenic translocations.
    Rowh MA; DeMicco A; Horowitz JE; Yin B; Yang-Iott KS; Fusello AM; Hobeika E; Reth M; Bassing CH
    Oncogene; 2011 Nov; 30(47):4757-64. PubMed ID: 21625223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel three-break rearrangement and cryptic translocations leading to colocalization of MYC and IGH signals in B-cell acute lymphoblastic leukemia.
    Tchinda J; Volpert S; Berdel WE; Büchner T; Horst J
    Cancer Genet Cytogenet; 2006 Mar; 165(2):180-4. PubMed ID: 16527615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody repertoires of four- and five-feature translocus mice carrying human immunoglobulin heavy chain and kappa and lambda light chain yeast artificial chromosomes.
    Nicholson IC; Zou X; Popov AV; Cook GP; Corps EM; Humphries S; Ayling C; Goyenechea B; Xian J; Taussig MJ; Neuberger MS; Brüggemann M
    J Immunol; 1999 Dec; 163(12):6898-906. PubMed ID: 10586092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The immunoglobulin heavy-chain gene 3' enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells.
    Duan H; Heckman CA; Boxer LM
    Oncogene; 2007 Apr; 26(18):2635-41. PubMed ID: 17043638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. c-myc expression is activated by the immunoglobulin kappa-enhancers from a distance of at least 30 kb but not by elements located within 50 kb of the unaltered c-myc locus in vivo.
    Mautner J; Behrends U; Hörtnagel K; Brielmeier M; Hammerschmidt W; Strobl L; Bornkamm GW; Polack A
    Oncogene; 1996 Mar; 12(6):1299-307. PubMed ID: 8649832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spatial proximity of translocation-prone gene loci in human lymphomas.
    Roix JJ; McQueen PG; Munson PJ; Parada LA; Misteli T
    Nat Genet; 2003 Jul; 34(3):287-91. PubMed ID: 12808455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Detection of minimal residual diseases in B-cell tumors using PCR specific for the immunoglobulin heavy chain gene].
    Matolcsy A; Borbényi Z; Demeter J; Egyed M; Fekete S; Földi J; Gergely L; Kajtár P; Kelényi G; Kiss A; László T; Lehoczky D; Losonczy H; Nagy M; Pál K; Pálóczy K; Radványi G; Semsei I; Varga G; Udvardy M
    Orv Hetil; 2000 Jun; 141(25):1403-6. PubMed ID: 10934884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concomitant downregulation of IgH 3' enhancer activity and c-myc expression in a plasmacytoma x fibroblast environment: implications for dysregulation of translocated c-myc.
    Thøger Andersen AS; Jensen AW; Grant P; Arulampalam V; Pettersson S; Junker S
    Mol Immunol; 1997 Feb; 34(2):97-107. PubMed ID: 9188842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. H-2/myc, E mu/myc, and c-myc transgenic mice: potent sources of early hematopoietic cell lines.
    Roland J; Morello D
    Cell Growth Differ; 1993 Nov; 4(11):891-900. PubMed ID: 8297795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a locus control region in the immunoglobulin heavy-chain locus that deregulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells.
    Madisen L; Groudine M
    Genes Dev; 1994 Sep; 8(18):2212-26. PubMed ID: 7958890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An additional segment at 1p36 derived from der(18)t(14;18) in patients with diffuse large B-cell lymphomas transformed from follicular lymphoma.
    Nomura K; Kanda-Akano Y; Shimizu D; Okuda T; Yoshida N; Matsumoto Y; Nishida K; Taki T; Yokota S; Horiike S; Taniwaki M
    Ann Hematol; 2005 Jul; 84(7):474-6. PubMed ID: 15700138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-range oncogenic activation of Igh-c-myc translocations by the Igh 3' regulatory region.
    Gostissa M; Yan CT; Bianco JM; Cogné M; Pinaud E; Alt FW
    Nature; 2009 Dec; 462(7274):803-7. PubMed ID: 20010689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular cytogenetics of IGH rearrangements in non-Hodgkin B-cell lymphoma.
    Bernicot I; Douet-Guilbert N; Le Bris MJ; Herry A; Morel F; De Braekeleer M
    Cytogenet Genome Res; 2007; 118(2-4):345-52. PubMed ID: 18000389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of IGH rearrangements in non-Hodgkin's B-cell lymphomas by fluorescence in situ hybridization.
    Bernicot I; Douet-Guilbert N; Le Bris MJ; Morice P; Abgrall JF; Berthou C; Morel F; De Braekeleer M
    Anticancer Res; 2005; 25(5):3179-82. PubMed ID: 16101124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deletional remodeling of c-myc-deregulating chromosomal translocations.
    Kovalchuk AL; Müller JR; Janz S
    Oncogene; 1997 Nov; 15(19):2369-77. PubMed ID: 9393881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.